157
Participants
Start Date
December 3, 2015
Primary Completion Date
November 29, 2016
Study Completion Date
November 29, 2016
Macimorelin
macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
Insulin
Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose
Krankenanstalt Rudolfstiftung, Vienna
Medical University & General Hospital of Vienna, AKH,, Vienna
Klinik für Endokrinologie, Diabetes und Ernährungsmedizin der Charité, Berlin
Clinical Centre of Serbia, Belgrade
Hospital de Conxo, Santiago de Compostela
San Luca Hospital, Milan
Clinical Centre of Vojvodina, Novi Sad
Hôpital Haut-Lévêque, Pessac
University Hospital Marburg, Marburg
RWTH Aachen University Hospital, Aachen
CHU de Lyon HCL-GH Est, Bron
Baylor College of Medicine-Endocrinology, Houston
Texas Diabetes and Endocrinology, Austin
Klinikum der LMU München, Munich
Max Planck Institut, Munich
Harbor UCLA Medical Center, Torrance
GHU Paris-Sud - Hôpital de Bicêtre, Le Kremlin-Bicêtre
VA Puget Sound Health Care System, Seattle
Swedish Medical Center - Cherry Hill, Seattle
Centrum Kliniczno-Badawcze, Elblag
Centrum Medyczne Angelius Provita, Katowice
Phase I - MTZ Clinical Research Sp. z o.o., Warsaw
Wromedica, Wroclaw
Hospital de Sant Pau, Barcelona
Hospital Universitari Vall d' Hebron, Barcelona
St Bartholomew's Hospital, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
AEterna Zentaris
INDUSTRY